New FDA Approval for Transpara AI Enhances Breast Cancer Detection at RSNA

Advancements in Breast Cancer Detection: Transpara's New FDA Approval

ScreenPoint Medical has announced exciting developments at the 110th annual meeting of the Radiological Society of North America (RSNA) taking place from December 1 to 4, 2024. The company's flagship product, Transpara, has received new authorization from the FDA, showcasing innovative features designed to enhance breast cancer detection rates. This state-of-the-art artificial intelligence tool has already set the benchmark in the medical field and is now poised to assist radiologists even more effectively.

Transpara, recognized as one of the most clinically validated AI solutions for breast cancer screening, provides specialists with an invaluable second opinion, helping to identify cancers at earlier stages and reducing the likelihood of unnecessary repeat examinations. During this year's RSNA event, ScreenPoint is demonstrating the updated version, Transpara 2.1, which incorporates advanced algorithms refined through additional training and global feedback from notable users.

Enhanced Features of Transpara 2.1

The latest iteration not only supports breast density options such as BIRADS and volumetric assessments but also introduces a groundbreaking temporal comparison feature. This allows current scans to be analyzed against up to three prior studies from the last six years, making it the first such tool available in the marketplace. The capabilities of this updated algorithm have been validated, positioning Transpara's performance within the top 10% of radiologists—an impressive achievement presented by Dr. Alejandro Rodríguez Ruiz at the recent ECR 2024.

Professor Nico Karssemeijer, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical, expressed excitement about the significant enhancements in Transpara's performance. He noted how the new features adapt well to radiologists' experiences, especially with intervals that provide more comprehensive context for analyzing findings. This serves to enrich the clinical workflow without significantly increasing the computational time.

The implications of these advancements extend to improving the overall efficiency of mammography screening processes. Numerous studies highlighting Transpara's benefits are being presented at RSNA, underscoring its positive impact on clinical workflows.

Key Studies Featuring Transpara

1. AI Triage Streamlining: Conducted by UMass Memorial Health, the study titled _“Putting It In Perspective AI Triage Streamlining Screening Mammogram Turnaround Time (Tat) Amid Staff Shortages”_ explored how AI could prioritize readings to reduce turnaround times in mammogram interpretation. The results underscored the software’s potential to alleviate workload stress, maximizing efficiency for radiologists.

2. Independent Third Reader: Another prominent study _“Implementación de un software de detección basado en redes neuronales convolucionales como un tercer lector independiente”_ assessed Transpara's role as a third-party reader in Germany's screening initiative. The findings indicated an increase in detection rates, particularly for invasive cancer types, reinforcing AI's value in enhancing cancer diagnosis accuracy.

3. Dense Breast Cases Performance: Additionally, a thorough evaluation was presented in _“Rendimiento de un sistema de inteligencia artificial en la detección de casos de tomosíntesis digital de mama en mamas densas y no densas”_. This study demonstrated that cases flagged by Transpara showed predictive cancer value regardless of breast density, marking a significant step in aiding radiologists working with diverse patient profiles.

With over 35 peer-reviewed publications, Transpara stands as the only AI algorithm for breast cancer validated across large-scale, real-world screening populations. The evidence indicates that using Transpara can cut interval cancer detection rates by up to 45%, while simultaneously easing physician workload.

The Future of AI in Breast Cancer Detection

ScreenPoint Medical continues to innovate, transforming cutting-edge machine learning research into practical tools that enhance radiologists' workflows and decision-making. Radiologists globally trust Transpara due to its rigorous development by experts in machine learning and image analysis, updated with extensive feedback from worldwide mammography professionals.

For more information and to access validation studies, visit ScreenPoint Medical.

With its commitment to improving clinical workflows and patient outcomes, ScreenPoint Medical remains at the forefront of advancing breast cancer detection technologies.